Indivior PLC (INDV)
| Market Cap | 3.79B |
| Revenue (ttm) | 1.18B |
| Net Income (ttm) | 74.00M |
| Shares Out | 124.85M |
| EPS (ttm) | 0.59 |
| PE Ratio | 51.36 |
| Forward PE | 10.78 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,032,315 |
| Open | 31.07 |
| Previous Close | 31.07 |
| Day's Range | 29.98 - 31.30 |
| 52-Week Range | 7.62 - 32.42 |
| Beta | 1.12 |
| Analysts | Strong Buy |
| Price Target | 32.50 (+7.16%) |
| Earnings Date | Oct 30, 2025 |
About INDV
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX T... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for INDV stock is "Strong Buy." The 12-month stock price target is $32.5, which is an increase of 7.16% from the latest price.
News
Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine
Medicaid and commercially insured patients with high adherence to SUBLOCADE® experienced lower relapse rates and reduced healthcare resource utilization Adherence to SUBLOCADE was associated with lowe...
Indivior PLC (INDV) Q3 2025 Earnings Call Transcript
Indivior PLC ( INDV) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Jason Thompson - Vice President of Investor Relations Joseph Ciaffoni - CEO & Director Patrick Barry - Chi...
Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance
Q3'25 Total Net Revenue of $314m, up 2% YOY; Q3'25 SUBLOCADE® Net Revenue of $219m, up 15% YOY Announces the Optimization of Rest of World (ROW) Business Discontinued the Sales and Marketing Support o...
Indivior to Participate in the Stifel 2025 Healthcare Conference
RICHMOND, Va. , Oct. 28, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ: INDV) today announced that it will participate in the Stifel 2025 Healthcare Conference: Stifel 2025 Healthcare Conference – New Yor...
Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th
RICHMOND, Va. , Oct. 16, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) today announced that it will report its third quarter 2025 financial results on Thursday, October 30, 2025, at 7:00 a.m.
Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment
Rapid induction with SUBLOCADE® showed higher treatment retention rates compared to standard induction, particularly among fentanyl-positive participants RICHMOND, Va. , Oct. 15, 2025 /PRNewswire/ -- ...
UK's Indivior to re-domicile to US after listing move
Indivior , said on Wednesday it plans to relocate its corporate domicile from the UK to the United States, establishing a new Delaware-based parent company, just months after the pharmaceutical firm m...
Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation
RICHMOND, Va. , Oct. 1, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) ("Indivior PLC" or the "Company") today announced that it intends to pursue a change in domicile from the U.K. to the U.S. and ...
Indivior PLC (INDV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Indivior PLC (NASDAQ:INDV) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 9:15 AM EDT Company Participants Joseph Ciaffoni - CEO & Director Ryan Preblick - Chief Financial ...
Indivior to Participate in Upcoming Investor Events
RICHMOND, Va. , Aug. 20, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ: INDV) today announced that it will participate in the following investor events: Morgan Stanley 23rd Annual Global Healthcare Confer...
Indivior's Strategic Turnaround Gains Traction Post-Q2 2025
Indivior's turnaround is driven by SUBLOCADE's strong growth, improved cash flow, and a three-phase recovery plan that the market undervalues. Q2 2025 results beat expectations, with SUBLOCADE deliver...
Indivior PLC (INDV) Q2 2025 Earnings Call Transcript
Indivior PLC (NASDAQ:INDV) Q2 2025 Earnings Conference Call July 31, 2025 8:00 AM ET Company Participants Jason Thompson - Vice President of Investor Relations Joseph J. Ciaffoni - CEO & Director Pat...
Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance
Q2'25 Total Net Revenue of $302m; Q2'25 SUBLOCADE® Net Revenue of $209m, up 9% Year-over-Year Indivior Action Agenda Underway to Strengthen Business and Generate Operational Momentum Conference Call S...
Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained
SLOUGH, United Kingdom and RICHMOND, Va. , July 25, 2025 /PRNewswire/ -- Further to the announcement made on June 2, 2025, Indivior PLC (Nasdaq: INDV) today announces that: (i) the secondary listing o...
Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder
Extended-release buprenorphine (BUP-XR) had lower rates of hospitalizations, emergency department (ED) visits, and outpatient physician office visits compared to those receiving daily oral buprenorphine...
Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st
RICHMOND, Va. , July 17, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced that it will report second quarter 2025 financial results on Thursday, July 31, 2025 at 7:00 a.m.
Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs
RICHMOND, Va. , July 8, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Vanessa Procter as Executive Vice President of Corporate Affairs, effective July 7, 20...
Indivior Announces Inclusion in the U.S. Russell 2000® and 3000® Indexes
RICHMOND, Va., June 30, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) will be added as a member of the U.S. small-cap Russell 2000® Index, effective after the U.S. market opens today as part ...
Indivior Appoints Tony Kingsley to the Board of Directors
RICHMOND, Va. , June 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Tony Kingsley to the Board of Directors as an Independent Non-Executive Director, eff...
Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users
A post-hoc analysis demonstrates that buprenorphine exposure with 300 mg SUBLOCADE® (buprenorphine extended-release) may improve treatment outcomes among opioid use disorder (OUD) patients with heavy ...
Indivior to delist from London Stock Exchange, maintain Nasdaq listing
Pharma firm Indivior said on Monday it will cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and better align...
Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained
SLOUGH, England and RICHMOND, Va. , June 2, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its intention to cancel: (i) the secondary listing of the Company's Ordinary Shares ("O...
Indivior Announces Patrick Barry as Chief Commercial Officer
Seasoned commercial executive with more than 30 years of pharmaceutical experience RICHMOND, Va. , May 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the appointment of Patri...
New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy
SUBLOCADE use during pregnancy showed no increased risk of birth defects, miscarriage, or maternal complications compared to general population rates RICHMOND, Va., May 1, 2025 /PRNewswire/ -- Indivio...
Indivior: Trying To Break Addiction
Indivior PLC's stock has seen headwinds recently due to increasing competition and poor performance but has potential for recovery with a new CEO and strategic changes. Sublocade, Indivior's key produ...